Filing Flows › Xeris Biopharma Holdings (XERS) › Guidance history
Xeris Biopharma Holdings (XERS) guidance history: what it guided and what it reported
Xeris Biopharma Holdings gave guidance in 3 earnings releases on file since May 7, 2026. Its releases raised guidance twice and lowered it 0 times.
Revenue
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $380M–$390M (May 7, 2026) → raised $385M–$390M (Aug 6, 2026) → raised $395M–$405M (Nov 5, 2026) | — | to be reported | — |
The latest quarter
Xeris Biopharma Holdings, Q3 2026: revenue $107M (+44% year over year), operating margin 15.8%, net earnings $11.3M, operating cash flow $35.5M. The chart follows the revenue to costs, profit and cash.
Questions
Does Xeris Biopharma Holdings beat its guidance?
Xeris Biopharma Holdings gave guidance in 3 earnings releases on file since May 7, 2026. Its releases raised guidance twice and lowered it 0 times.
How often does Xeris Biopharma Holdings raise guidance?
Its earnings releases raised guidance twice and lowered it 0 times since May 7, 2026.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.